Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

StemCells, Inc. Strengthens Senior Executive Team

Published: Thursday, June 19, 2014
Last Updated: Thursday, June 19, 2014
Bookmark and Share
Company appoints Joel Naor, Naymisha Patel and Mohammad A. El-Kalay and promote Stephen Huhn to the position of vice president.

StemCells, Inc. has announced one promotion and three new appointments to the Company's executive team. Stephen Huhn, M.D., F.A.C.S., F.A.A.P. has been promoted to the newly created position of vice president, CNS clinical research and chief medical officer. Joel Naor, M.D., M.B.A., M.Sc., has joined StemCells, Inc. as vice president, clinical development, ophthalmology, and will report to Dr. Stephen Huhn; Naymisha Patel has joined StemCells, Inc. as vice president, quality systems; and Mohammad A. El-Kalay, Ph.D. has joined StemCells, Inc. as vice president, process development. Dr. Huhn, Ms. Patel and Dr. El-Kalay will report to Martin McGlynn president and chief executive officer of StemCells, Inc.

"We are pleased to welcome Dr. Naor, Ms. Patel and Dr. El-Kalay to StemCells, Inc., and Dr. Huhn to his new position, at this critical point in the Company's evolution," said Martin McGlynn. "We plan to initiate our first controlled Phase II studies in spinal cord injury and dry age related macular degeneration (AMD) this year. Dr. Huhn's combined background in neurosurgery and academic research, together with his demonstrated leadership of our clinical activities, have prepared him well to assume his new role as our chief medical officer. Dr. Naor's 14 years of clinical experience, with a focus on eye related disorders, will be instrumental for the success of our dry AMD program. Ms. Patel's experience in building and leading quality organizations and Dr. El-Kalay's operational management and process development experience will be invaluable as we look beyond the planned Phase II studies towards additional pivotal studies and the commercialization phase."

As chief medical officer, Dr. Huhn will continue to oversee all aspects of the Company's clinical activities. Dr. Huhn joined StemCells, Inc. in January 2007 to direct the Company's preclinical and clinical development programs for CNS indications. Prior to joining the company, he was associate professor of neurosurgery at Stanford University and chief of pediatric neurosurgery at the Lucile Salter Packard Children's Hospital.

Dr. Huhn earned his M.D. at the University of Arizona in 1987 and completed a residency in neurosurgery at the University of Maryland in 1993. He completed a fellowship in neuro-oncology at UCSF Medical Center in San Francisco and pediatric neurosurgery at Northwestern University's Children's Memorial Hospital in Chicago.

Dr. Huhn is certified by the American Board of Neurological Surgery and the American Board of Pediatric Neurological Surgery and is a fellow in the American College of Surgeons and the American Academy of Pediatrics. Dr. Huhn maintains an unpaid consulting associate professor appointment with the department of neurosurgery at Stanford University.

Dr. Naor brings more than 14 years of experience drug development for retinal conditions, and will be responsible for the development of cell-based products for retinal diseases, initially from the Company's proprietary HuCNS-SC® platform technology. To that end, he will oversee the Company's planned Phase II trial in dry AMD. Most recently Dr. Naor served as the vice president and head of global medical affairs at Santen Inc. Dr. Naor was previously vice president of drug development and new ventures at Ora Inc., chief medical officer of Macusight, senior director at Allergan, and a director at QLT. He also had key roles in the development of a Sirolimus formulation for intravitreal and subconjunctival administration, Ozurdex®, Trivaris™, and Visudyne®. Dr. Naor earned his M.D. from the Technion - Israel Institute of Technology and following a residency in ophthalmology, he underwent cornea and external disease training at the University of Toronto where he also obtained an M.Sc. in epidemiology. Dr. Naor holds a M.B.A. from Simon Fraser University in Vancouver, Canada.

Naymisha Patel will be responsible for driving the corporate quality agenda and implementing Quality Management Systems appropriate for our planned clinical and manufacturing growth. Ms. Patel has over 18 years of experience in the field and was most recently executive director of quality assurance at Geron Corporation, where she was responsible for quality and regulatory affairs compliance strategy and implementation. She previously held roles of increasing responsibility at Nektar Therapeutics and Aerogen, Inc. Ms. Patel earned a B.S. in zoology from Maharaja Sayajirao University in India, a B.A. in chemistry from California State University, Hayward, and an M.B.A. in Management from Northcentral University, Arizona. Ms. Patel is a certified quality auditor by the American Society of Quality and holds a regulatory affairs certification from Regulatory Affairs Professional Society.

Mohammad A. El-Kalay, Ph.D., will be responsible for developing scalable and efficient manufacturing processes and assays to meet the increasing clinical and development demand for products. Mohammad has over 25 years of operational and management leadership and was most recently co-founder, president and CEO of EyeCyte, Inc. an early stage company developing therapies to treat acquired and inherited retinal diseases. Dr. El-Kalay previously held roles of increasing responsibility in research, product and process development at MicroIslet, Telos Pharmaceuticals, MorphoGen Pharmaceuticals, Osiris Therapeutics, Pfizer, SyStemix and Applied ImmuneSciences. He has also served as consultant and scientific advisory board member for several companies. He earned his B.Sc. in chemical engineering and his M.Sc. and Ph.D. in biomedical engineering at Strathclyde University, Glasgow.

In connection with their hire, the Company has granted Ms. Patel, Dr. Naor and Dr. El-Kalay an aggregate total of 510,000 restricted stock units (RSUs). Each grant was made pursuant to the Company's 2012 Commencement Incentive Plan and in accordance with Nasdaq Listing Rule 5635(c)(4) concerning inducement grants to new employees.

Each RSU gives the holder the right to receive upon vesting, without cash payment, a share of StemCells common stock. All of these granted RSUs have four-year vesting schedules so that they vest in four equal parts on each of their first four service anniversaries, starting in 2015 and ending in 2018.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

StemCells, Inc. Appoints Dr. Alan Trounson
Company announces appointment of Dr. Trounson to its Board of Directors.
Thursday, July 10, 2014
StemCells, Inc. Announces Closure of Enrollment in Phase I/II Dry AMD Trial
Phase II clinical trial to begin this year.
Tuesday, June 24, 2014
StemCells Inc. Advances Clinical Trial in AMD to Final Cohort
Phase I/II AMD trial on track to complete enrollment in June.
Saturday, May 24, 2014
StemCells, Inc. Appoints Greg Schiffman as Chief Financial Officer
Mr. Schiffman will join Company’s executive team, effective January 1, 2014.
Friday, November 15, 2013
StemCells Initiates Phase I/II Clinical Trial in Dry Age-Related Macular Degeneration
Leading cause of blindness in elderly.
Thursday, June 28, 2012
StemCells Initiates Phase I/II Clinical Trial in Dry Age-Related Macular Degeneration
Leading cause of blindness in elderly.
Thursday, June 28, 2012
StemCells, Inc. Announces Publication of Preclinical Data Demonstrating Its Human Neural Stem Cells Preserve Vision
HuCNS-SC(R) cells (purified human neural stem cells) found to protect host photoreceptors and preserve vision in an animal model of retinal disease.
Monday, January 30, 2012
StemCells, Inc. Announces Closing of Public Offering of Common Stock and Warrants
The company announced that it has closed its previously announced underwritten offering of an aggregate of 8,000,000 units and 8,000,000 Series B Warrants, each to purchase one unit, at a public offering price of $1.25 per unit.
Friday, December 23, 2011
Stemcells, Inc. To Present At 2011 Stem Cell Meeting
StemCells, Inc. have announced that Martin McGlynn, President and CEO, will present a business update at the 2011 Forum.
Tuesday, November 29, 2011
World’s First Neural Stem Cell Transplant in Spinal Cord Injury Patient
The transplant surgery was performed by a team of surgeons led by Dr. Raphael Guzman and Dr. K. Min.
Monday, September 26, 2011
Stemcells, Inc. Awarded CIRM Planning Grant to Pursue Preclinical Development of HuCNS-SC Cells for Alzheimer’s Disease
CIRM has approved the Company’s application for a “Disease Team Therapy Development Planning Award.”
Friday, September 02, 2011
StemCells Regains Compliance for Continued NASDAQ Global Market Listing
Company has received notification from The NASDAQ stock market that the Company has regained compliance with the minimum bid price requirement.
Friday, July 22, 2011
Stemcells, Inc. Relocates Corporate Headquarters and U.S. Research Labs
Corporate headquarters and U.S.-based research and development operations relocate to 7707 Gateway Blvd, Newark, CA 94560, USA.
Wednesday, July 20, 2011
Stemcells to Present Clinical Evidence of Long-term Survival of HuCNS-SC® Cells Following Completion of Immunosuppression Regimen
The data will be reported at the International Society for Stem Cell Research (ISSCR) 9th Annual Meeting, June 15-18 in Toronto, Ontario.
Thursday, June 16, 2011
StemCells, Inc. Reports First Quarter Financial Results and Announces Reduction in Force
Company to reduce US-based workforce by 30 percent to reduce its cash burn rate and extends financial resources to focus on advancing the clinical development of HuCNS-SC® cells.
Friday, May 06, 2011
Scientific News
Sorting Through Cellular Statistics
Aaron Dinner, professor in chemistry, and his graduate student Herman Gudjonson are trying to read the manual of life, DNA, as part of the Dinner group’s research into bioinformatics—the application of statistics to biological research.
Playing 'Tag' with Pollution lets Scientists See Who's It
Using a climate model that can tag sources of soot from different global regions and can track where it lands on the Tibetan Plateau, researchers have determined which areas around the plateau contribute the most soot — and where.
Women’s Immune System Genes Operate Differently from Men’s
A new technology reveals that immune system genes switch on and off differently in women and men, and the source of that variation is not primarily in the DNA.
Long Telomeres Associated with Increased Lung Cancer Risk
Genetic predisposition for long telomeres predicts increased lung adenocarcinoma risk.
First Artificial Ribosome Designed
Researchers at the University of Illinois at Chicago and Northwestern University have engineered a tethered ribosome that works nearly as well as the authentic cellular component, or organelle, that produces all the proteins and enzymes within the cell.
High-Resolution 3D Images Reveal the Muscle Mitochondrial Power Grid
NIH mouse study overturns scientific ideas on energy distribution in muscle.
Expanding the Brain
A team of researchers has identified more than 40 new “imprinted” genes, in which either the maternal or paternal copy of a gene is expressed while the other is silenced.
Identifying a Key Growth Factor in Cell Proliferation
Researchers discover that aspartate is a limiter of cell proliferation.
Study Uncovers Target for Preventing Huntington’s Disease
Scientists from Cardiff University believe that a treatment to prevent or delay the symptoms of Huntington’s disease could now be much closer, following a major breakthrough.
Paving the way to Better Ovarian Cancer Diagnosis
Aïcha BenTaieb will present her invention for automated identification of ovarian cancer’s many subtypes at an international conference this fall.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!